BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN5668 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN5668\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04590326-11311@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:REGN5668: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:REGN5668\, phase 1/2\, Ovarian Cancer.\nStudy: A Study to Find 
 Out How Safe REGN5668 is and How Well it Works In Adult Women When Given W
 ith Either Cemiplimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstimat
 ed primary completion: 8 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/regn5668#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04590326
URL:https://assetmemo.bio/drug/regn5668#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
